FDA Approves Pirtobrutinib For Treatment of Adult Patients With CLL, SLL

Pirtobrutinib is the first and only non-covalent BTK inhibitor to be approved by the FDA and is indicated for adult patients who already received at least 2 prior lines of therapy.

Related Keywords

Williamg Wierda ,Jacob Van Naarden ,Brian Koffman ,Eli Lilly ,Md Anderson Cancer Center ,Department Of Leukemia ,University Of Texas ,Cancer Center ,